MA53234A - Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques - Google Patents
Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiquesInfo
- Publication number
- MA53234A MA53234A MA053234A MA53234A MA53234A MA 53234 A MA53234 A MA 53234A MA 053234 A MA053234 A MA 053234A MA 53234 A MA53234 A MA 53234A MA 53234 A MA53234 A MA 53234A
- Authority
- MA
- Morocco
- Prior art keywords
- masp
- diseases
- methods
- treating various
- thrombotic disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688611P | 2018-06-22 | 2018-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53234A true MA53234A (fr) | 2022-04-20 |
Family
ID=68984236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053234A MA53234A (fr) | 2018-06-22 | 2019-06-20 | Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20200140570A1 (fr) |
| EP (1) | EP3836965A4 (fr) |
| JP (1) | JP2021527698A (fr) |
| KR (1) | KR20210024003A (fr) |
| CN (1) | CN112638417A (fr) |
| AU (2) | AU2019288459B2 (fr) |
| BR (1) | BR112020025841A2 (fr) |
| CA (1) | CA3104083A1 (fr) |
| CL (1) | CL2020003324A1 (fr) |
| EA (1) | EA202190106A1 (fr) |
| GE (3) | GEAP202515541A (fr) |
| IL (1) | IL279588A (fr) |
| JO (1) | JOP20200328A1 (fr) |
| MA (1) | MA53234A (fr) |
| MX (1) | MX2020013755A (fr) |
| PH (1) | PH12020552188A1 (fr) |
| SG (1) | SG11202012627UA (fr) |
| WO (1) | WO2019246367A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI867422B (zh) * | 2020-03-06 | 2024-12-21 | 美商奥默羅斯公司 | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 |
| CN120173118B (zh) * | 2020-12-16 | 2025-09-16 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| AU2022216290A1 (en) * | 2021-02-05 | 2023-09-14 | Omeros Corporation | Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19 |
| JP2024518724A (ja) * | 2021-04-25 | 2024-05-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途 |
| AU2022288660A1 (en) * | 2021-06-08 | 2024-01-18 | Jiangxi Jemincare Group Co., Ltd. | Anti-masp-2 antibody and use thereof |
| CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| EP4489782A4 (fr) * | 2022-03-10 | 2026-03-25 | Omeros Corp | Inhibiteurs de masp-2 et masp-3, et compositions et méthodes associées pour le traitement de la drépanocytose |
| CN115125299A (zh) * | 2022-08-09 | 2022-09-30 | 大连珍奥药业股份有限公司 | Masp1在筛选预防和/或治疗心血管疾病的药物中的应用 |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| WO2025076476A2 (fr) | 2023-10-06 | 2025-04-10 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004216176B2 (en) * | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| ES2541134T3 (es) * | 2003-05-12 | 2015-07-16 | Helion Biotech Aps | Anticuerpos de MASP-2 |
| PL2465534T3 (pl) * | 2004-06-10 | 2017-08-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20140056873A1 (en) * | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| WO2006033386A1 (fr) * | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | Anticorps igg4 humains stabilises |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| KR20200015952A (ko) * | 2012-06-18 | 2020-02-13 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| LT3057993T (lt) * | 2013-10-17 | 2020-11-25 | Omeros Corporation | Gydymo būdai būklių, susijusių su nuo masp-2 priklausomu komplemento aktyvinimu |
| US20150353623A1 (en) * | 2014-04-03 | 2015-12-10 | Loma Linda University | Substances and methods for the treatment of cerebral amyloid angiopathy related conditions or diseases |
| US20170137537A1 (en) * | 2015-11-09 | 2017-05-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
-
2019
- 2019-06-20 KR KR1020217001375A patent/KR20210024003A/ko not_active Ceased
- 2019-06-20 GE GEAP202515541A patent/GEAP202515541A/en unknown
- 2019-06-20 AU AU2019288459A patent/AU2019288459B2/en active Active
- 2019-06-20 JP JP2020571365A patent/JP2021527698A/ja active Pending
- 2019-06-20 EA EA202190106A patent/EA202190106A1/ru unknown
- 2019-06-20 EP EP19823617.6A patent/EP3836965A4/fr active Pending
- 2019-06-20 MX MX2020013755A patent/MX2020013755A/es unknown
- 2019-06-20 US US16/447,085 patent/US20200140570A1/en not_active Abandoned
- 2019-06-20 SG SG11202012627UA patent/SG11202012627UA/en unknown
- 2019-06-20 WO PCT/US2019/038188 patent/WO2019246367A1/fr not_active Ceased
- 2019-06-20 JO JOP/2020/0328A patent/JOP20200328A1/ar unknown
- 2019-06-20 GE GEAP202516147A patent/GEP20267851B/en unknown
- 2019-06-20 CA CA3104083A patent/CA3104083A1/fr active Pending
- 2019-06-20 BR BR112020025841-5A patent/BR112020025841A2/pt unknown
- 2019-06-20 GE GEAP201915541A patent/GEP20257785B/en unknown
- 2019-06-20 CN CN201980041741.5A patent/CN112638417A/zh active Pending
- 2019-06-20 MA MA053234A patent/MA53234A/fr unknown
-
2020
- 2020-12-16 PH PH12020552188A patent/PH12020552188A1/en unknown
- 2020-12-20 IL IL279588A patent/IL279588A/en unknown
- 2020-12-21 CL CL2020003324A patent/CL2020003324A1/es unknown
-
2022
- 2022-11-03 US US18/052,371 patent/US20230212314A1/en not_active Abandoned
-
2025
- 2025-05-21 US US19/214,827 patent/US20260062499A1/en active Pending
-
2026
- 2026-02-06 AU AU2026200868A patent/AU2026200868A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019288459B2 (en) | 2025-11-13 |
| GEP20257785B (en) | 2025-08-11 |
| AU2026200868A1 (en) | 2026-02-26 |
| GEP20267851B (en) | 2026-01-26 |
| JOP20200328A1 (ar) | 2020-12-15 |
| CN112638417A (zh) | 2021-04-09 |
| CL2020003324A1 (es) | 2021-04-23 |
| CA3104083A1 (fr) | 2019-12-26 |
| GEAP202515541A (en) | 2025-03-10 |
| US20230212314A1 (en) | 2023-07-06 |
| WO2019246367A1 (fr) | 2019-12-26 |
| AU2019288459A1 (en) | 2021-02-04 |
| MX2020013755A (es) | 2021-05-12 |
| US20200140570A1 (en) | 2020-05-07 |
| US20260062499A1 (en) | 2026-03-05 |
| IL279588A (en) | 2021-03-01 |
| EP3836965A4 (fr) | 2022-04-20 |
| JP2021527698A (ja) | 2021-10-14 |
| BR112020025841A2 (pt) | 2021-03-23 |
| KR20210024003A (ko) | 2021-03-04 |
| SG11202012627UA (en) | 2021-01-28 |
| EA202190106A1 (ru) | 2021-04-13 |
| PH12020552188A1 (en) | 2021-06-28 |
| AU2019288459A2 (en) | 2021-03-18 |
| EP3836965A1 (fr) | 2021-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53234A (fr) | Compositions et procédés d'inhibition de masp-2 pour le traitement de divers troubles et maladies thrombotiques | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP2861246A4 (fr) | Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies | |
| EP3969597A4 (fr) | Compositions et procédés pour le traitement de maladies médiées par l'atpase | |
| EP3947715A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3894392A4 (fr) | Compositions et procédés pour le traitement du cancer | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP3917539A4 (fr) | Compositions et procédés de traitement des troubles neurocognitifs | |
| EP3866781A4 (fr) | Nouvelles compositions pour le traitement de maladies inflammatoires | |
| EP3781214A4 (fr) | Compositions et procédés de traitement de l'amyotrophie spinale | |
| EP3612215A4 (fr) | Compositions et procédés pour le traitement d'inflammation pulmonaire | |
| EP3937932A4 (fr) | Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses | |
| EP3973047A4 (fr) | Procédés et compositions pour le traitement de troubles hépatiques | |
| EP3761970A4 (fr) | Compositions et procédés pour le traitement de maladies neurologiques | |
| MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
| EP3908601A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP3448421A4 (fr) | Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales | |
| EP3952881A4 (fr) | Compositions et procédés pour le traitement d'inconfort des lentilles de contact | |
| MA52961A (fr) | Compositions et procédés pour la réduction ou le traitement d'une inflammation | |
| EP3866777A4 (fr) | Polythérapie pour le traitement de maladies inflammatoires | |
| EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
| EP3484534A4 (fr) | Procédés et compositions de polymère pour le traitement du décollement de la rétine et d'autres troubles oculaires | |
| MA49651A (fr) | Compositions et procédés pour traiter des maladies associées à un défaut d'empreinte |